Kathrin Schwedler

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study

Frédéric Amant, Gϋnter von Minckwitz, Sileny Han et al. · Journal of Clinical Oncology · 2013 · 371 citations · Full text

Medicine, Obstetrics, Oncology +17

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

Gϋnter von Minckwitz, Kathrin Schwedler, Marcus Schmidt et al. · European Journal of Cancer · 2011 · 184 citations

Medicine, Oncology, Pharmacotherapy +17

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial

Volkmar Müller, Stephan Gade, Bettina Steinbach et al. · Breast Cancer Research and Treatment · 2014 · 121 citations

Medicine, Cancer Biology, Oncology +16

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study

Sibylle Loibl, Kathrin Schwedler, Gϋnter von Minckwitz et al. · Annals of Oncology · 2007 · 115 citations · Full text

Medicine, Oncology, Pharmacology +5